TITLE

The Economic Impact of the Diagnosis of Dysplasia in Barrett's Esophagus

AUTHOR(S)
Ofman, Joshua J.; Lewin, Klaus; Ramers, Christian; Ippoliti, Andy; Lieberman, David; Weinstein, Wilfred
PUB. DATE
October 2000
SOURCE
American Journal of Gastroenterology;Oct2000, Vol. 95 Issue 10, p2946
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: Cost-effective strategies for identifying patients with Barrett's esophagus who are most likely to develop cancer have not been developed. Surveillance endoscopy is currently used, and we hypothesized that more frequent surveillance intervals would identify patients with "transient positive" diagnoses of dysplasia--dysplasia found on one examination but not on subsequent ones. Our aim was to explore the potential economic impact of transient positive diagnoses of dysplasia on alternative surveillance strategies over a 10-yr period. METHODS: Data were derived from a 2-yr randomized, prospective study comparing omeprazole to ranitidine in 95 patients with Barrett's esophagus. A transient positive diagnosis of dysplasia was defined as a patient who was diagnosed with dysplasia during the study period but whose 24-month biopsies revealed no dysplasia. We calculated the number of transient positive diagnoses of dysplasia and modeled the potential economic impact of a diagnosis of dysplasia over a 10-yr period. RESULTS: Thirty patients (31%) had at least one reading of dysplasia during the study period. Nineteen patients (20%) had a transient positive diagnosis of dysplasia. During the study period, no cancers were found. A surveillance strategy of every other year and every 6 months for dysplasia would result in 1072 endoscopies over a 10-yr period at a discounted cost of $1,587,184. A total of 61% of endoscopies would be because of transient positive diagnoses of dysplasia. A strategy of yearly surveillance and every 6 months for dysplasia would result in 1404 endoscopies at a discounted cost of $2,096,733, of which 28% would result from transient positive diagnoses of dysplasia. The discounted incremental costs of more frequent surveillance in this cohort of patients over 10 yr is $509,549. CONCLUSIONS: Based on current practice strategies, transient positive diagnoses of dysplasia account for 28-61% of endoscopies in Barrett's surveillance programs. This analysis suggests that the endoscopy workload and costs associated with surveillance could be substantially reduced if patients with transient positive diagnoses of dysplasia reverted to usual surveillance after two negative examinations.
ACCESSION #
17624301

 

Related Articles

  • Esophageal Adenocarcinoma Associated with Barrett's Esophagus: Long--term Management with Laser Ablation. Ertan, Atilla; Zimmerman, Michael; Younes, Mamoun // American Journal of Gastroenterology;Dec1995, Vol. 90 Issue 12, p2201 

    We report the use of neodymium:yttrium-aluminum-garnet (Nd:YAG) laser ablation to treat high-grade dysplasia and intramucosal esophageal adenocarcinoma associated with Barrett's esophagus in a patient who refused surgery. Throughout laser therapy, the patient received omeprazole 40 mg/day. After...

  • The economics of early detection of high grade dysplasia in patients with barrett's esophagus. Provenzale, D. // Journal of the Royal College of Surgeons of Edinburgh;Aug2000, Vol. 45 Issue 4, p273 

    Features a cost-utility analysis which evaluates the risks and the benefits of surveillance of patients with Barrett's esophagus. Estimates of cancer risk; Impact of surveillance on the quality of life of patients undergoing surveillance and esophagectomy; Detection of high grade dysplasia.

  • Tumor necrosis factor-α in Barrett's oesphagus: a potential novel mechanism of action. Tselepsis, Chris; Perry, Ian; Dawson, Chris; Hardy, Rob; Darnton, S. Jane; McConkey, Chris; Stuart, Rob C.; Wright, Nick; Harrison, Rebecca; Jankowski, Janusz Antoni Z. // Oncogene;9/5/2002, Vol. 21 Issue 39, p6071 

    Provides information on a study which assessed the tumor necrosis factor-α in Barrett's metaplasia and examined if it can promote &beta-catenin mediated transcription of oncogenes in a gastrointestinal model system. Occurrence of Barrett's metaplasia in esophageal inflammation; Mechanism of...

  • Can extent of high grade dysplasia in Barrett's oesophagus predict the presence of adenocarcinoma at oesophagectomy? Dar, M.S.; Goldblum, J.R.; Rice, T.W.; Falk, G.W. // Gut;Apr2003, Vol. 52 Issue 4, p486 

    Background: Optimal management of Barrett's oesophagus complicated by high grade dysplasia is controversial. Recently, the extent of high grade dysplasia was described as a predictor of subsequent development of cancer in patients undergoing continued surveillance. However, there is no universal...

  • PHOTODYNAMIC THERAPY USING MTHPC FOR EARLY BARRETT'S-ASSOCIATED OESOPHAGEAL CANCERS. Jamieson, N.F.; Thorpe, S.; Mosse, A.; Brown, S.G.; Lovat, L.B. // Gut;Apr2003 Supplement 1, Vol. 52, pA46 

    Background: Oesophageal adenocarcinoma is rising in incidence and is strongly associated with Barrett's oesophagus. Oesophagectomy is the standard treatment for early carcinoma but has considerable morbidity and mortality. Photodynamic therapy (PDT) is a non-thermal minimally invasive technique...

  • Pathological characteristics of esophageal cancer. HONG-YUN SHI; SHU-CHAI ZHU; WEN-BIN SHEN; MIAO-LING LIU // Oncology Letters;2014, Vol. 8 Issue 2, p533 

    The pathological characteristics of esophageal squamous cell carcinoma, which include regularly occurring multiple carcinogenic lesions (MLs), severe dysplasia (SD) and direct intramural infiltration (DI), were investigated using large pathological sections. A total of 52 esophageal cancer...

  • Prevalence and Prognostic Significance of Neuroendocrine Cells in Esophageal Adenocarcinoma. Hamilton, Katherine; Chiappori, Alberto; Olson, Sandy; Sawyers, John; Johnson, David; Washington, Kay // Modern Pathology;May2000, Vol. 13 Issue 5, p475 

    Neuroendocrine differentiation is common in adenocarcinomas of the stomach and colon and may be associated with a slightly better prognosis in gastric adenocarcinoma. We studied neuroendocrine differentiation in esophageal adenocarcinomas and associated Barrett's esophagus (BE) to determine...

  • Developments in endoscopic technology for oesophageal cancer. Bigio, I.J.; Bown, S.G.; Kelley, C.; Lovat, L.; Pickard, D.; Ripley, PM. // Journal of the Royal College of Surgeons of Edinburgh;Aug2000, Vol. 45 Issue 4, p267 

    Reports on the first stages of a clinical study designed to test the elastic-scattering spectroscopy (ESS) method for identification of dysplasia in Barrett's esophagus. Surveillance of Barrett's esophagus for dysplasia; Sensitivity of ESS to the sizes and structures of the sub-cellular...

  • Barrett's Esophagus at a Tertiary Care Center: Association of Age on Incidence and Prevalence of Dysplasia and Adenocarcinoma. Guardino, Jason M.; Khandwala, Farah; Lopez, Rocio; Wachsberger, Don M.; Richter, Joel E.; Falk, Gary W. // American Journal of Gastroenterology;Oct2006, Vol. 101 Issue 10, p2187 

    OBJECTIVES: Barrett's esophagus (BE) is traditionally thought of as a disease of middle-aged Caucasian men. Little is known about BE in younger patients. We sought to assess the effect of age on features of BE including the prevalence and incidence of dysplasia and carcinoma. METHODS: All...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics